Thereactorthat Areva is buildinginFinlandmight havedispelledworries about the commercial viability ofnewplants, were itnot behind schedule and overbudget itself.
One problem: There may be warnings about cardiac and other side effects on the drug's label, although Iannini thinks these worries have been largely dispelled.